Treatments for obesity, such as glucagon-like peptide 1 (GLP-1) analogues (liraglutide and semaglutide), can be used.67 Early identification of those metabolic changes and their proper treatment are crucial to reduce CVR in women with POS. The gene discussed is GLP1R; the disease is Obesity.